



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit 1614

In re Patent Application of:

Richard B. Mazess et al.

Filed: June 27, 2003

Application No.: 10/608,480

Confirmation No.: 7844

Examiner: Not Assigned

Entitled: MULTI-USE VESSELS FOR  
VITAMIN D FORMULATIONS

I, Sally J. Sorensen, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Sally Sorensen  
Signature

January 7, 2004  
Date of Signature

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(b)(3)**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Forms PTO/SB/08A and PTO/SB/08B. Copies of the references are attached. Citation of these references is respectfully requested.

In accordance with 37 CFR 1.97(b)(3) these references are provided before the mailing of a first Office Action on the merits.


No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,

Jeffrey D. Peterson  
Jeffrey D. Peterson  
Reg. No. 49,038

**File No: 017620-9373**  
Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
(608) 257-3501

Q:\client\017620\9373\B0279728.1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 1				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Name Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	017620-9373

**U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------


	AA	2,383,446	Calcott et al.	06/04/41
	AB	3,697,559	DeLuca et al.	10/10/72
	AC	3,741,996	DeLuca et al.	06/26/73
	AD	3,907,843	DeLuca et al.	09/23/75
	AE	4,160,803	Potts	07/10/79
	AF	4,195,027	DeLuca et al.	03/25/80
	AG	4,202,829	DeLuca et al.	05/13/80
	AH	4,225,596	DeLuca et al.	09/30/80
	AI	4,234,495	DeLuca et al.	11/18/80
	AJ	4,260,549	DeLuca et al.	04/07/81
	AK	4,362,710	Watanabe	12/07/82
	AL	4,391,802	Suda et al.	07/05/83
	AM	4,508,651	Baggiolini et al.	04/02/85
	AN	4,554,106	DeLuca et al.	11/19/85
	AO	4,555,364	DeLuca et al.	11/19/85
	AP	4,588,716	DeLuca et al.	05/13/86
	AQ	4,661,294	Holick et al.	04/28/87
	AR	4,689,180	DeLuca et al.	08/25/87
	AS	4,698,328	Neer et al.	10/06/87

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Name Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	1	Attorney Docket Number	017620-9373


U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

	AT	4,717,721	DeLuca et al.	01/25/88	
	AU	4,833,125	Neer et al.	05/23/89	
	AV	4,866,048	Calverley et al.	09/12/89	
	AW	4,902,481	Clark et al.	02/20/90	
	AX	5,063,221	Nishii et al.	11/05/91	
	AY	5,104,864	DeLuca et al.	04/14/82	
	AZ	5,141,719	Fernwood et al.	08/25/92	
	BA	5,157,135	Tsuji et al.	10/20/92	
	BB	5,205,989	Aysta	04/27/93	
	BC	5,219,528	Clark	06/15/93	
	BD	5,232,836	Bouillon et al.	08/03/93	
	BE	5,264,184	Aysta et al.	11/23/93	
	BF	5,264,618	Felgner et al.	11/23/93	
	BG	5,334,740	Takahashi et al.	08/02/94	
	BH	5,338,532	Tomalia et al.	08/16/94	
	BI	5,372,996	Labrie	12/13/94	
	BJ	5,403,831	DeLuca et al.	04/04/95	
	BK	5,417,923	Bojanic et al.	05/23/95	
	BL	5,488,120	Knutson et al.	01/30/96	
	BM	5,527,524	Tomalia et al.	06/18/96	
Examiner Signature				Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute of form 1449/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/608,480
				<b>Filing Date</b>	June 27, 2003
				<b>First Name Inventor</b>	Richard B. Mazess
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	Unknown
<b>Sheet</b>	3	<b>of</b>	1	<b>Attorney Docket Number</b>	017620-9373

**U.S. PATENT DOCUMENTS**

Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
	BN	5,554,386	Groman et al.	09/10/96
	BO	5,597,575	Breitbarth	01/28/97
	BP	5,602,116	Knutson et al.	02/11/97
	BQ	5,614,513	Knutson et al.	03/25/97
	BR	5,637,742	Valles et al.	06/10/97
	BS	5,661,025	Szoka, Jr. et al.	08/26/97
	BT	5,691,328	Peterson et al.	11/25/97
	BU	5,739,271	Sridhar et al.	04/14/98
	BV	5,795,882	Bishop et al.	08/18/98
	BW	6,521,608	Henner et al.	02/18/03
	BX	6,537,982	Bishop et al.	03/25/03

**FOREIGN PATENT DOCUMENTS**

Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	BY	Belgium	877 356	Wisconsin Alumni Research Foundation	10/15/79		
	BZ	Japan	5320127	Nisshin Flour Milling Co.	09/29/93		
	CA	Japan	6025039	Kurary Co. Ltd.	02/01/94		
	CB	Japan	62000033	General Hospital	10/15/86		
	CC	EP	0197514	General Hospital	10/15/86		

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	1	of	6	Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	CS	Aloia, J. et al., <i>Amer. J. Med.</i> , (1988) 84:401-08.
	CT	Barton, D. et al., "Synthetic Uses of Steroidal Ring & Diene Protection: 22,23-Dihydroergosterol," <i>JCS Perkin I</i> , (1976) pp. 821-826.
	CU	Beer, et al., "A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies," <i>Cancer</i> , (June 15, 2001) 91:12:2431-2439.
	CV	Beer, et al., "Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer," <i>Seminars in Oncology</i> , Suppl 15 (August 2001) 28:4:49-55.
	CW	Beer, T. et al., "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
	CX	Blazsek, I. et al. "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 $\alpha$ ,25 Dihydroxyvitamin D <sub>3</sub> , and Prednisone," 16:4:259-264 (Abstract).
	CY	Brautbar, N. "Osteoporosis: Is 1,25-(OH)2D <sub>3</sub> of Value in Treatment?" <i>Nephron</i> (1986) 44:161-166.
	CZ	Braunwald, E. et al., <i>Harrison's Principles of Internal Medicine</i> : Part Eleven, "Disorders of Bone and Mineral Metabolism," Chapter 335, McGraw-Hill, New York, (1987) pp. 1860-1865.
	DA	Brown, J.P. et al., "Serum Bone Gla-Protein: A Specific Marker for Bone Formation in Postmenopausal Osteoporosis," <i>Lancet</i> , (1984) 1:1091-1093.
	DB	Caniggia, A. et al., "Effect of a Long-Term Treatment with 1,25-Dihydroxyvitamin D <sub>3</sub> on Osteocalcin in Postmenopausal Osteoporosis," <i>Calcified Tissue Int.</i> , (1986) 38:328-332.
	DC	Christiansen, C. et al., "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," <i>Europ J Clin Invest.</i> , (1980) 10:273-279.
	DD	Christiansen, C. et al., <i>Eur. J. Clin. Invest.</i> , (1981) 11:305-309.
	DE	Crump, D.R. et al., "(22S)-Hydroxyvitamin D <sub>4</sub> ," <i>J.C.S. Perkins Trans. I</i> , (1973) pp. 2731-2733.
	DF	Cho, Y.L. et al., "Combined Effects of 1,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
	DG	Defacque, H. et al., "Different Combinations of Retinoids and Vitamin D <sub>3</sub> Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
	DH	DeLuca et al., "Synthesis, Biological Activity, and Metabolism of 22,23- <sup>3</sup> H-Vitamin D <sub>4</sub> ," <i>Arch. Biochem, Biophys.</i> , (1968) 124:122-128.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

1

**Complete if Known**

Application Number	10/608,480
Filing Date	June 27, 2003
First Name Inventor	Richard B. Mazess
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	017620-9373

**U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	CD	EP	0390097	Nisshin Flour Milling Co.	10/03/90	
	CE	EP	0562497	Nisshin Flour Milling Co.	09/29/93	
	CF	EP	0503630	Kuraray Co. Ltd.	09/16/92	
	CG	EP	0664287	Duphar International	07/26/95	
	CH	PCT	WO 84/04527	Wisconsin Alumni Research Foundation	11/22/84	
	CI	PCT	WO 87/00834	Leo Pharmaceutical Products, Ltd.	02/12/87	
	CJ	PCT	WO 90/10620	Wisconsin Alumni Research Foundation	09/20/90	
	CK	PCT	WO 92/05130	Lunar Corporation	04/02/92	
	CL	PCT	WO 92/12165	Lunar Corporation	07/23/92	
	CM	PCT	WO 92/21355	Procter & Gamble	12/10/92	
	CN	PCT	WO 93/07883	ISIS Pharmaceuticals	04/29/93	
	CO	PCT	WO 93/14763	Lunar Corporation	08/05/93	
	CP	PCT	WO 94/16711	Lunar Corporation	08/04/94	
	CQ	PCT	WO 96/40153	Bone Care International	12/19/96	
	CR	PCT	WO 99/49870	Oregon Health Sciences	10/07/99	


Q:\client\017620\9373\B0275177.1

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	6	Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

DI	Duda et al., "1,25-Dihydroxyvitamin D Stimulation Test for Osteoblast Function in Normal and Osteoporotic Postmenopausal Women," <i>J. Clinic Inves.</i> , (1987) 79:1249-1253.
DJ	Endo, K. et al., "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
DK	Foldes, J. et al., "Long Term Treatment with 1 $\alpha$ (OH)D <sub>3</sub> for Postmenopausal Osteoporosis: Efficacy and Safety," <i>Osteoporosis</i> , (1987) 2:971-973.
DL	Gallagher, J.C., et al., "Treatment of Postmenopausal Osteoporosis with High Doses of Synthetic Calcitriol," <i>Annals of Int. Med.</i> , (1990) 13:649-655.
DM	Gallagher, J.C. et al., "Effects of Increasing Doses of 1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> on Calcium Homeostasis in Postmenopausal Osteopenic Women," <i>J. Bone Min. Res.</i> , (1994) 9:5:607-614.
DN	Grab, W. Z. <i>Physiol. Chem.</i> , (1936) 243:63-89.
DO	Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, (1979) pp. 5-6.
DP	Hershberger, P. et al. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
DQ	Hoikka, V. et al., "Treatment of Osteoporosis with 1-Alpha-Hydroxycholecalciferol and Calcium," <i>Acta. Med. Scand.</i> (1980) 207:221-224.
DR	Holick, M.F. et al., "Identification of 1,25-Dihydroxycholecalciferol, a Form of Vitamin D <sub>3</sub> Metabolically Active in the Intestine," <i>Proc. Natl. Acad. Sci. USA</i> , (1971) 68:803-804.
DS	Holick, M.F. et al., "1 $\alpha$ -Hydroxy Derivative of Vitamin D <sub>3</sub> : A Highly Potent Analog of 1 $\alpha$ ,25 Dihydroxyvitamin D <sub>3</sub> ," <i>Science</i> (1973) pp. 180, 190-191.
DT	Holick, M.F., "Noncalcemic Actions of 1,25-Dihydroxyvitamin D <sub>3</sub> and Clinical Applications", <i>Bone</i> , (1995) 17:2:107S-110S.
DU	Horst et al., "Quantitation of Vitamin D and its Metabolites and Their Plasma Concentrations in Five Species of Animals," <i>Anal. Biochem.</i> , (1981) 116:189-203.
DV	Horst et al., "Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick," <i>Biochem. J.</i> , (1982) 204:185-189.

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	3	of	6	Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--


	DW	Jensen, G.F. et al., "Treatment of Post Menopausal Osteoporosis. A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D <sub>3</sub> and Calcium," <i>Clin. Endocrinol.</i> , (1982) 16:515-524.
	DX	Johnson, C. et al., "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
	DY	Jones, G. et al., "Isolation and Identification of 1,25-Dihydroxyvitamin D <sub>2</sub> ," <i>Biochemistry</i> , (1975) 14:1250-1256.
	DZ	Kanis, J.A. et al., "Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis," <i>Osteoporosis Int.</i> , (1991) 1:182-188.
	EA	Kim, S. et al., "Potentiation of 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone, <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
	EB	Knutson, et al., "Metabolism of 1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> to activated Dihydroxyvitamin D <sub>2</sub> Metabolites Decreases Endogenous 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> in Rats and Monkeys," <i>Endocrinology</i> , (1995) 136:11:4749-4753.
	EC	Kocienski, P.J. et al., "Calciferol and its Relatives. A Synthesis of Vitamin D <sub>4</sub> ," <i>J.C.S. Perkins I</i> , (1979) pp. 1290-1293.
	ED	Lam, H.Y. et al., <i>Science</i> , (1974) 486:1038-1040.
	EE	Londowski, J.M. et al., "Biological Activity of the C-1, C-3, C-25, $\beta$ -D-Glucopyranosides of 1,25-Dihydroxyvitamin D <sub>3</sub> <sup>1</sup> ," <i>J. Pharmacology Expr. Ther.</i> , (1986) 237:3:837-840.
	EF	Majewski, et al., "Inhibition of Tumor Cell-Induced Angiogenesis by Retinoids, 1,25-Dihydroxyvitamin D <sub>3</sub> and their Combination," <i>Cancer Letters</i> , (1993) 75:35-39.
	EG	Martin and DeLuca, "Calcium Transport," <i>Am. J. Physiol.</i> , 216:1352-1359.
	EH	Mathias, C.J. et al., "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.
	EI	McDonald, F.G., "The Multiple Nature of Vitamin D," <i>J. Biol. Chem.</i> 114, (1936) 1xv.
	EJ	<i>Merck Index</i> , S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930
	EK	Miller et al., "The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> <sup>1</sup> ," <i>Cancer Res.</i> , (1992) 52:515-520.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute Form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	4	of	6	Attorney Docket Number	017620-9373
-------	---	----	---	------------------------	-------------

**Complete if Known**

Application Number	10/608,480
Filing Date	June 27, 2003
First Named Inventor	Richard B. Mazess
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--

EL	Moffatt, K. et al., "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.
EM	Muindi, J. et al., "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology &amp; Therapeutics</i> , (Dec. 2002) pp. 648-659.
EN	Nemeto, H. et al., "A Stereoselective Synthesis of 1 $\alpha$ - Hydroxy-Vitamin D <sub>3</sub> ," <i>CHEMISTRY LETTERS</i> , (1985) 8:1131-1132.
EO	Orimo, H. et al., "Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1 $\alpha$ (OH)-Vitamin D <sub>3</sub> ," <i>Bone and Mineral</i> , (1987) 3:47-52.
EP	Ott, S.M. and C.H. Chesnut, <i>Annals of Int. Med.</i> , (1989) 110:267-274.
EQ	Paaren et al., "Direct C(1) Hydroxylation of Vitamin D <sub>3</sub> and Related Compounds," <i>J. Org. Chem.</i> , (1980) 45:3253.
ER	Packman, K. et al. "Combination Treatment of MCF-7 Xenografts with the Vitamin D <sub>3</sub> Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.
ES	Podenphant, J. et al., "Serum Bone Gla Protein and Other Biochemical Estimates of Bone Turnover in Early Postmenopausal Women During Prophylactic Treatment for Osteoporosis," <i>Acta Med Scand</i> , (1985) 218:329-333.
ET	<i>Physician's Desk Reference</i> , Edition 43:1746-1748.
EU	Pouilles, J.M. et al., "Prevention of Early Postmenopausal Bone Loss with 1 $\alpha$ -Hydroxy Vitamin D <sub>3</sub> , A Three-Year Prospective Study," <i>Clin Rheumatol.</i> 11, 4 (1992) pp. 492-497.
EV	Ravid, A. et al., "1,25-Dihydroxyvitamin D <sub>3</sub> Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.
EW	Reeve, L.E. et al., "Biological Activity of 1 $\alpha$ -hydroxy Vitamin D <sub>2</sub> in the Rat," <i>Arch. Biochem. Biophys.</i> (Feb. 1978) 186:1:164-167.
EX	Sato, F. et al., "Biological Activity of 1 $\alpha$ ,25-Dihydroxyvitamin D Derivatives - 24- <i>epi</i> -1 $\alpha$ ,25-Dihydroxyvitamin D-2 and 1 $\alpha$ ,25-Dihydroxyvitamin D-7," <i>Biochim. Biophys. Acta</i> , (1991) 1091:188-192.
EY	Shiraki, M. et al., <i>Endocrinol. Japan</i> , (1985) 32:305-315.
EZ	Siwinska, A. et al. "Potentiation of the Antiproliferative Effect <i>in Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	5	of	6	Attorney Docket Number	017620-9373
-------	---	----	---	------------------------	-------------

**Complete if Known**

Application Number	10/608,480
Filing Date	June 27, 2003
First Named Inventor	Richard B. Mazess
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--

FA	Sjoden et al., "Effects of 1 OHD <sub>2</sub> on Bone Tissue," <i>Acta. Endocrinol.</i> (Copenh.) (Aug. 1984) 16:4:564-568.
FB	Sjoden, G. et al., "Antirachitic Activity of 1 $\alpha$ -Hydroxyergocalciferol and 1 $\alpha$ -Hydroxycholecalciferol in Rats," <i>J. Nutr.</i> , (1984) 114:2043-2046.
FC	Sjoden, G. et al., "1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> is Less Toxic than 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> in the Rat," <i>Proc. Soc. Exp. Biol. Med.</i> , (1985) 178:432-436.
FD	Skowronski et al., "Actions Of Vitamin D <sub>3</sub> Analogs on Human Prostrate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D <sub>3</sub> ," <i>Endocrinology</i> , (1995) 136:20-26.
FE	Skowronski et al., "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D <sub>3</sub> Receptors and Actions in Human Prostate Cancer Cell Lines," <i>Endocrinology</i> , (1993) 132:1952-1960.
FF	Slapak, C. et al., "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
FG	Sommerfeldt et al., "Metabolism of Orally Administered [ <sup>3</sup> H]Ergocalciferol and [ <sup>3</sup> H]Cholecalciferol by Dairy Calves," <i>J. Nutr.</i> , (1983) 11:2595-2600.
FH	Song, X.D. et al., "Bryostatin-1 and 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
FI	Sorensen, O.H. et al., <i>Clin. Endocrinol.</i> , (1977) 7:169S-175S.
FJ	Studzinski, G. et al., "Potentiation by 1- $\alpha$ ,25- Dihydroxyvitamin D <sub>3</sub> of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
FK	Strugnell et al., "Metabolism of a Cyclopropane-Ring-Containing Analog of 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> in a Hepatocyte Cell Model," <i>Biochem. Pharm.</i> , (1990) 40:333-341.
FL	Strugnell et al., "1 $\alpha$ ,24(S)-Dihydroxyvitamin D <sub>2</sub> : a biologically active product of 1 $\alpha$ -hydroxyvitamin D <sub>2</sub> made in the human hepatoma, Hep3B," <i>Biochem. J.</i> , (1995) 310:233-241.
FM	Suzuki, Y. et al., "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
FN	Swami, S. et al. "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
FO	Tachibana, Y. (Nisshin Flour Milling Co.), "Preparation of 1Beta-Hydroxyvitamin D <sub>2</sub> and D <sub>3</sub> ," <i>CHEMICAL ABSTRACTS</i> , (1990) 113:1:6688 Col. 2 Abstract No. 6683y.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/608,480
				Filing Date	June 27, 2003
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	6	of	6	Attorney Docket Number	017620-9373

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--

	FP	Tanaka, Y. et al., <i>Endocrinology</i> (1973) 92:417-422.
	FQ	Torres, R. et al., "Etoposide Stimulates 1,25-Dihydroxyvitamin D <sub>3</sub> Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
	FR	Tsuji, M. et al., "Synthesis of 22,23-Dihydro-1 $\alpha$ ,25-Dihydroxyvitamin D <sub>2</sub> and its 24R-Epimer, New Vitamin D <sub>2</sub> Derivatives," <i>Bull. Chem. Soc. Jpn.</i> , (1990) 63:8:2233-2238.
	FS	Wang, Q. et al., "1,25-Dihydroxyvitamin D <sub>3</sub> and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
	FT	Wang, X. et al., "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
	FU	Wientroub, S. et al. "The Dichotomy in the Effects of 1,25 Dihydroxy Vitamin D <sub>3</sub> and 24, 25 Dihydroxy Vitamin D <sub>3</sub> on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats," <i>Calcif. Tissue Int.</i> , (1987) 40:166-172.
	FV	Windaus, A. et al., "Uber das Krystallisierte Vitamin D <sub>4</sub> ," <i>Z. Physiol. Chem.</i> , (1937) 247:185-188.
	FW	Yu, W. et al., "Enhancement of 1,25- Dihydroxyvitamin D <sub>3</sub> - Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.
	FX	Zerwekh et al., "Short-Term 1,25-Dihydroxyvitamin D <sub>3</sub> Administration Raises Serum Osteocalcin in Patients with Postmenopausal Osteoporosis," <i>J. Clin. Endocrinol. Metabol.</i> , (1985) 60:615-617.

Q:\client\017620\9373\B0275176.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.